Key Highlights
- Shares of NVS declined approximately 2% during pre-market trading following disappointing first-quarter financial results
- Quarterly revenue totaled $13.11B, falling short of Wall Street’s $13.40B projection and representing a 1% year-over-year decline
- The blockbuster heart medication Entresto saw sales plummet 42% to $1.31B following U.S. patent expiration and generic market entry
- Core earnings per share decreased to $1.99 compared to $2.28 in the prior-year period; core operating income declined 12% to $4.9B
- Chief Executive Vas Narasimhan cautioned that America’s “most favored nation” pharmaceutical pricing framework could restrict European and Japanese patient access to innovative therapies within the next year and a half
Novartis delivered underwhelming first-quarter performance for 2026, with financial metrics falling below projections as generic rivalry created more significant headwinds than market watchers anticipated.
[[LINK_START_0]]https://twitter.com/marketsday/status/2049011476711768279?s=20[[LINK_END_0]]Quarterly revenue registered at $13.11 billion, undershooting the $13.40 billion Wall Street consensus estimate. Core operating income retreated 12% to $4.9 billion, likewise missing the approximately $5.1 billion projection from Visible Alpha.
The primary driver behind the shortfall was Entresto, the pharmaceutical giant’s flagship cardiovascular therapy. Revenue from this medication tumbled 42% to $1.31 billion following the expiration of U.S. patent protection and subsequent generic market penetration. Market analysts had anticipated $1.37 billion in sales.
Last year, Entresto represented 14% of aggregate net revenue, positioning this as among the company’s most significant patent cliff challenges in its recent corporate timeline. Chief Executive Vas Narasimhan has characterized it as the most substantial patent expiration Novartis has encountered in twenty years.
The challenges extend beyond Entresto alone. Promacta, used for blood disorders, and Tasigna, a leukemia medication, are similarly confronting generic market pressures, compounding the revenue growth challenges.
Core earnings per share contracted to $1.99, down from $2.28 during the comparable quarter last year. Operating income decreased 9% while net income dropped 13%, mirroring both the revenue underperformance and elevated research expenditures.
Chief Financial Officer Mukul Mehta informed journalists that the performance aligned with the company’s internal projections. He indicated the organization anticipates “growth to return back to our P&L in the second half of this year.”
Novartis maintained its full-year outlook, highlighting a robust development pipeline and continuing product commercializations. The organization projects annual sales to contract by approximately $4 billion this year attributable to generic competition affecting Entresto, Promacta, and Tasigna.
Chief Executive Highlights MFN Policy Concerns
Beyond the quarterly financial disclosure, CEO Narasimhan utilized the earnings announcement to voice apprehensions regarding U.S. pharmaceutical pricing regulations, particularly the “most favored nation” framework.
The MFN regulation links American drug costs to prices established in other developed nations. Narasimhan cautioned the ramifications would extend internationally, stating “the reality of MFN is going to set in in the next 18 months.”
He indicated Novartis is advocating for Europe and Japan to reconsider their pharmaceutical pricing and reimbursement methodologies. Absent modifications, he cautioned that “novel medicines might see delayed entry” and patient treatment availability could diminish.
Presently, the immediate impact on Novartis remains modest. MFN currently affects approximately 5% to 10% of Medicaid-associated revenue. However, Narasimhan views the regulation as permanent. “I don’t see it disappearing in the U.S.,” he stated.
His statements mirror concerns from industry counterparts. Roche and AstraZeneca have similarly identified Europe’s pricing infrastructure as an escalating threat to future medication accessibility.
Analyst Sentiment Remains Moderately Optimistic
Notwithstanding the earnings disappointment, Wall Street maintains a generally favorable outlook on the stock. Novartis carries a Moderate Buy consensus rating derived from six analyst evaluations.
The consensus price objective stands at $169.86, suggesting approximately 17% appreciation potential from present trading levels.
Entresto will confront patent expirations throughout Europe beginning in November, which will introduce additional revenue pressures during the year’s second half.
